28341065|t|Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia
28341065|a|This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β1-42, tau, and phosphorylated tau in the diagnostic evaluation of patients with dementia. The recommendations were developed by a multidisciplinary working group based on the available evidence and consensus from focused discussions for (i) identification of Alzheimer's disease (AD) as the cause of dementia, (ii) prediction of rate of decline, (iii) cost-effectiveness, and (iv) interpretation of results. The working group found sufficient evidence to support a recommendation to use CSF AD biomarkers as a supplement to clinical evaluation, particularly in uncertain and atypical cases, to identify or exclude AD as the cause of dementia. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Operational recommendations for the interpretation of ambiguous CSF biomarker results were also provided.
28341065	0	15	Recommendations	T078	C0034866
28341065	20	23	CSF	T031	C0007806
28341065	24	26	AD	T047	C0002395
28341065	27	37	biomarkers	T201	C0005516
28341065	45	55	diagnostic	T060	C0430022
28341065	56	66	evaluation	T058	C0220825
28341065	70	78	dementia	T048	C0497327
28341065	84	91	article	T170	C1706852
28341065	101	116	recommendations	T078	C0034866
28341065	131	138	Grading	T185	C0441800
28341065	142	157	Recommendations	T078	C0034866
28341065	159	169	Assessment	T058	C0220825
28341065	171	182	Development	T169	C1527148
28341065	188	205	Evaluation method	T062	C2911685
28341065	215	235	clinical application	T058	C4084924
28341065	239	258	cerebrospinal fluid	T031	C0007806
28341065	260	263	CSF	T031	C0007806
28341065	265	278	amyloid-β1-42	T116,T123	C0169424
28341065	280	283	tau	T116,T123	C0085401
28341065	289	303	phosphorylated	T116	C1519061
28341065	304	307	tau	T116,T123	C0085401
28341065	315	325	diagnostic	T060	C0430022
28341065	326	336	evaluation	T058	C0220825
28341065	340	348	patients	T101	C0030705
28341065	354	362	dementia	T048	C0497327
28341065	368	383	recommendations	T078	C0034866
28341065	404	421	multidisciplinary	T057	C0242479
28341065	422	435	working group	T098	C1883562
28341065	459	467	evidence	T078	C3887511
28341065	472	481	consensus	T054	C0376298
28341065	515	529	identification	UnknownType	C0679807
28341065	533	552	Alzheimer's disease	T047	C0002395
28341065	554	556	AD	T047	C0002395
28341065	565	570	cause	UnknownType	C0679233
28341065	574	582	dementia	T048	C0497327
28341065	589	599	prediction	T078	C0681842
28341065	603	607	rate	T081	C1521828
28341065	611	618	decline	T046	C0234985
28341065	626	644	cost-effectiveness	T081	C0010181
28341065	655	680	interpretation of results	T058	C3526596
28341065	686	699	working group	T098	C1883562
28341065	717	725	evidence	T078	C3887511
28341065	739	753	recommendation	T078	C0034866
28341065	761	764	CSF	T031	C0007806
28341065	765	767	AD	T047	C0002395
28341065	768	778	biomarkers	T201	C0005516
28341065	784	794	supplement	T169	C2348609
28341065	798	806	clinical	T062	C0008972
28341065	807	817	evaluation	T058	C0220825
28341065	835	844	uncertain	T033	C0087130
28341065	849	857	atypical	T080	C0205182
28341065	858	863	cases	T077	C1706256
28341065	888	890	AD	T047	C0002395
28341065	898	903	cause	UnknownType	C0679233
28341065	907	915	dementia	T048	C0497327
28341065	941	949	evidence	T078	C3887511
28341065	958	967	uncertain	T033	C0087130
28341065	976	979	CSF	T031	C0007806
28341065	980	982	AD	T047	C0002395
28341065	983	993	biomarkers	T201	C0005516
28341065	994	1004	outperform	T169	C0884358
28341065	1005	1023	imaging biomarkers	T201	C0005516
28341065	1025	1036	Operational	T062	C0683955
28341065	1037	1052	recommendations	T078	C0034866
28341065	1061	1075	interpretation	T169	C1285553
28341065	1079	1088	ambiguous	T080	C2346729
28341065	1089	1092	CSF	T031	C0007806
28341065	1093	1102	biomarker	T201	C0005516
28341065	1103	1110	results	T033	C0683954